GlassScriptPhysician profile
Robert L Whitson
NPI 1528171410
$1,743.71
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $389.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $487.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $293.28 | 2019 | |
| Daiichi Sankyo INC. | $190.85 | 2019 | |
| Allergan, INC. | $169.44 | 2019-2020 | |
| Lilly USA, LLC | $163.74 | 2019-2020 | |
| Pfizer INC. | $131.36 | 2019-2020 | |
| Genzyme Corporation | $81.62 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.44 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $50.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.01 | 2019 | |
| Ironshore Pharmaceuticals INC. | $17.54 | 2019 | |
| Merck Sharp & Dohme LLC | $16.46 | 2019 | |
| Antares Pharma, INC. | $16.21 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.94 | 2020 | |
| Circassia INC. | $13.59 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strongbridge US INC. | $12.00 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Whitson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.